Haemonetics Corporation: stock overview

HAENYSEHealthcare · Surgical & Medical Instruments & Apparatus

Price

$122.94

November 13, 2026Market cap $5.6B

DCF calculator

What Ploutos Investor adds for Haemonetics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from FY2010
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

Haemonetics had revenue of $1.4B over the last 12 months and net income of $104M, a net margin of 7.5%. Revenue grew by 8.9% a year on average over the last 5 years. At $122.94 the shares trade at a P/E of 53.8, against a median of 36.9 over the last 5 fiscal years. It has net debt of $863M. It pays no dividend.

From its SEC filings (latest fiscal year to March 28, 2026) and the price of November 13, 2026.

Its SEC filings
Market cap
$5.6B
45.45M shares
P/E
53.8
Today53.8
Median36.9
Revenue, 12 months
$1.4B
+8.9% a year over 5 years
Net margin
7.5%
FY2025: 0.0%, above 49% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

FY2024–FY2026 fiscal years

+0.9% a year over 2 years

  • FY2026Mar 28, 202610-K
    Revenue$1.3B
  • FY2025Mar 29, 202510-K
    Revenue$1.4B
  • FY2024Mar 30, 202410-K
    Revenue$1.3B

Fiscal years in figures

HAE's revenue, profit, cash flow and dividend with each year-end price, from FY2010 to FY2023, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $3.0B
$5.6B
Enterprise value 
$6.5B
P/E 3-year median: 26.4
53.8
EV / EBIT 
36.5
EV / Revenue 
4.7
P/B 3-year median: 3.7
6.2
FCF yield 3-year median: 4.7%
5.3%
Earnings yield 3-year median: 3.8%
1.9%

Profitability

Gross margin 
59.6%
Operating margin 
12.8%
Net margin 3-year median: 9.0%
7.5%
ROIC 
6.3%
ROIC, 5-year average 
6.8%
ROE 
12.1%

Growth

Revenue, yearly change 
-2.0%
EPS, yearly change 
-38.1%
FCF, yearly change 
+82.8%
Revenue, average a year 
+8.9%
EPS, average a year 
+5.8%

The yearly change compares FY2026 with FY2025.

Balance sheet

Cash 
$261M
Total debt 
$1.1B
Net debt 
$863M
Net debt / EBITDA 
3.0x
Interest cover 
9.2x
Current ratio 
2.84

Balance sheet of September 26, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
3.13%
Total returned 
3.13%
Shares, yearly change 
-5.4%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 38).

Gross margin

59.0%

Above 54% of the 161 companies in its industry, and 77% of all.

Operating margin

11.8%

Above 65% of the 186 companies in its industry, and 68% of all.

Net margin

0.0%

Above 49% of the 189 companies in its industry, and 34% of all.

ROE

0.0%

Above 47% of the 174 companies in its industry, and 31% of all.

ROA

0.0%

Above 48% of the 190 companies in its industry, and 34% of all.

Revenue growth

-2.0%

Above 19% of the 186 companies in its industry, and 23% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
HAEMONETICS CORP
CIK
313143
Exchange
NYSE
Industry (SIC)
3841 · Surgical & Medical Instruments & Apparatus
Fiscal year ends
April 3
Latest annual report
March 28, 2026
Reporting currency
USD
Shares
45.45M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Haemonetics's filings show?

These are Haemonetics's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about HAE

Didn't find what you were looking for?

Ask us
What is HAE's market cap?

Haemonetics Corporation's market cap is $5.6B, at a price of $122.94 on November 13, 2026 and 45.45M shares.

What is HAE's P/E?

HAE's P/E is 53.8, on earnings per share of $2.26 over the last 12 months. The median over the last 5 fiscal years was 36.9.

How much revenue does HAE have?

Haemonetics had revenue of $1.4B over the last 12 months. Over the last 5 years it changed by +8.9% a year on average.

Does HAE pay a dividend?

No. Haemonetics paid no regular dividend over the last 12 months.

Where do the figures come from?

From Haemonetics Corporation's SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.